Paragon expansion to address ‘deficit in gene therapy CDMO capacity’

By Dan Stanton contact

- Last updated on GMT

Paragon says the new plant's location near Baltimore international airport is critical for making personalised medicines. GettyImages/LewisTsePuiLung
Paragon says the new plant's location near Baltimore international airport is critical for making personalised medicines. GettyImages/LewisTsePuiLung
The CDMO says it is building a 150,000 square-foot biomanufacturing facility in Maryland in preparation for a double-digit growth in the gene therapy space.

Paragon Bioservices’ facility in Baltimore, US will make clinical batches of gene therapies for customers by the fourth quarter 2014, with commercial manufacturing capabilities offered in the next two years.

According to CEO Pete Buzy, “the growing need for broad gene therapy manufacturing capacity from its current and future client base,”​ has driven the expansion, financials of which he did not divulge.

“There's also a significant deficit in gene therapy CDMO capacity that will mostly grow over the next three to five years,”​ he told Biopharma-Reporter. “Paragon believes the space will increase by double digits in the foreseeable future.”

While the plant will be equipped with several 500L and 2000L single-use bioreactors, Buzy said many of the contract development and organisation’s (CDMO) clients are in the orphan disease or rare disease markets, which will not require such large capacity.

“Paragon is using a variety of vendors, and the selection is based on what best fits the needs of its clients and their processes,”​ Buzy said, though did not name specific vendors.

Buzy added the facility’s location, near to Baltimore/Washington International Thurgood Marshall (BWI) Airport, is a critical advantage as time is critical for patients who receive personalised therapies.

Related products

show more

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 22-Jul-2019 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Related suppliers

Follow us

Products

View more

Webinars